Author's posts
Venturing A Perspective On The Drug Pricing Debate
Offering an early stage biotech investor’s view on the drug pricing debate.
The Creation Of Biotech Startups: Evolution Not Revolution
Models for creating new biotech companies have evolved enormously over the past two decades. Recently, two articles proposed applying Tech-like models of company creation to the world of biotech. As a biotech investor, the author provides some historic…
Biotech Startups And The Hard Truth Of Innovation
Gary Pisano’s recent Harvard Business Review piece, The Hard Truth About Innovative Cultures, beautifully frames up how innovative corporate environments are frequently misunderstood. The author shares some color commentary from the perspective of a b…
Getting Clinical On New Drug Launches
The IQVIA Institute released a data-rich report in April 2019 on the state of clinical R&D in the US pharmaceutical industry; the author examines a number of the trends in clinical trial activity outlined in the findings.
Sharing An Innate Desire To Address Inflammation: Novartis And IFM Team Up
Today Novartis announced the acquisition of IFM Therapeutics’ portfolio of NLRP3 antagonists, via the purchase of IFM Tre, a subsidiary of IFM
Sharing The Adaptive Ski Experience With The Biotech Community
Author explores the strong connection between the work done in the biotech field with adaptive sports through his first hand experience as a coach.
Sharing The Adaptive Ski Experience With The Biotech Community
Author explores the strong connection between the work done in the biotech field with adaptive sports through his first hand experience as a coach.
Biotech Insider Stock Sales: Peer Benchmarks And Guidelines
Understanding the right strategy as an insider for stock sales is a challenge. The author examines peer benchmarking data and suggested guidelines for insider stock sales by CEOs and other biotech executives following their IPOs.
Venture Volatility: 2018’s Banner Year Closed Cautiously For Biotech
2018 was a gangbuster year for biotech VC-funding into startups, but the year ended with significant downward volatility. Author provides a quick review of the data and things to watch.
The Game Isn’t Worth The Candle: Reflections On The JPM Healthcare Conference
The “JPM week” in San Fran is an annual kickoff for the industry. After a weekend to reflect, I come away more concerned than ever about the event and our industry.
